Every year, world‑leading dementia researcher Dr Jeffrey Cummings releases a global snapshot of Alzheimer’s trials – and the 2026 update has just been published. Right now, researchers are evaluating 158 medicines across 192 trials – marking an impressive 40% rise over the past decade. This year’s review also shows the most diverse Alzheimer’s drug pipeline to date.

The global effort to find a cure for Alzheimer’s disease has seen a 35% increase in the number of clinical trials and a 40% increase in therapies being tested since 2016, according to a new report from a UNLV researcher.

Local experts Cameron Belt, the senior economist and research director for RCG Economics, and Shawn McCoy, Ph.D., director of the Lied Center for Real Estate at UNLV, will analyze and discuss potential solutions to this critical issue facing our community.

The federal government’s restrictive control of a fair chunk of the remaining land left for development in the Las Vegas Valley is now weighing heavily on the region’s housing market, according to multiple sources.

Las Vegas medical school study shows 35% increase in clinical trials since 2016.

The U.S. Supreme Court restored broad access to the abortion pill Mifepristone, at least for now, allowing women to obtain the medication at pharmacies, through telehealth or through the mail without an in-person visit to a doctor.

As of two weeks ago, marijuana belonged to the same controlled-substance classification as heroin and LSD. But on April 23, the U.S. Department of Justice reclassified medicinal and FDA-approved cannabis from Schedule I to Schedule III, the group that also includes lower-risk, less-abused drugs such as ketamine and steroids. What does this mean for Nevada’s commercial marijuana industry? That part remains unclear, at least in the short term.

The final rule from the Office of the Attorney General places all drug products that contain marijuana and are federally approved in Schedule III of the Controlled Substances Act. The move shifts cannabis from Schedule I, alongside substances like heroin and LSD, to Schedule III, with the likes of codeine and ketamine.